Patent intelligence · US
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
Patent details — US 12344676
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 1, 2025
- Expiration
- Jun 26, 2045
- Applicant
- PRECISION BIOLOGICS, INC.
- Claims
- 7
- CPC classes
- A61K, A61K2039/505, A61K39/39558, A61K45/06
Quick answer
US 12344676 (Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers) is held by PRECISION BIOLOGICS, INC.. Status: granted. Granted Jul 1, 2025. Expires Jun 26, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PRECISION BIOLOGICS, INC.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K2039/505, A61K39/39558, A61K45/06, A61K47/6859, A61K47/6863
More from PRECISION BIOLOGICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12419920
Bifidobacterium longum NCIMB 41676
granted -
US 12410418
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12232492
Disinfection of bacteriophages products using supercritical carbon dioxide
granted -
US 12233135
Therapeutic constructs for treating cancer
granted -
US 12180463
Lactobacillus reuteri
granted
Frequently asked questions
What is US patent 12344676?
US 12344676 (Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers) is held by PRECISION BIOLOGICS, INC.. Status: granted. Granted Jul 1, 2025. Expires Jun 26, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12344676?
PRECISION BIOLOGICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.
When does US 12344676 expire?
Our index shows an expiration date of Jun 26, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.